141 related articles for article (PubMed ID: 29474549)
1. PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Sakamoto Y; Yamagishi S; Tanizawa Y; Tajimi M; Okusaka T; Ojima H
Jpn J Clin Oncol; 2018 Apr; 48(4):396-399. PubMed ID: 29474549
[TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
3. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
[TBL] [Abstract][Full Text] [Related]
5. mTOR Inhibitors in Advanced Biliary Tract Cancers.
Wu CE; Chen MH; Yeh CN
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30682771
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
[TBL] [Abstract][Full Text] [Related]
7. Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Kaavya J; Mahalaxmi I; Devi SM; Santhy KS; Balachandar V
J Cell Physiol; 2019 Jun; 234(6):8259-8273. PubMed ID: 30370571
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
[TBL] [Abstract][Full Text] [Related]
9. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
10. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
11. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
12. Src as a Therapeutic Target in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
[TBL] [Abstract][Full Text] [Related]
13. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.
Ojima H; Yoshikawa D; Ino Y; Shimizu H; Miyamoto M; Kokubu A; Hiraoka N; Morofuji N; Kondo T; Onaya H; Okusaka T; Shimada K; Sakamoto Y; Esaki M; Nara S; Kosuge T; Hirohashi S; Kanai Y; Shibata T
Cancer Sci; 2010 Apr; 101(4):882-8. PubMed ID: 20088962
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
Jin L; Jin MH; Nam AR; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Lett; 2017 Dec; 411():162-170. PubMed ID: 29024814
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.
Corti F; Nichetti F; Raimondi A; Niger M; Prinzi N; Torchio M; Tamborini E; Perrone F; Pruneri G; Di Bartolomeo M; de Braud F; Pusceddu S
Cancer Treat Rev; 2019 Jan; 72():45-55. PubMed ID: 30476750
[TBL] [Abstract][Full Text] [Related]
16. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
Nam HJ; Kim HP; Yoon YK; Song SH; Min AR; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Invest New Drugs; 2012 Dec; 30(6):2148-60. PubMed ID: 22197904
[TBL] [Abstract][Full Text] [Related]
17. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways as therapeutic targets in biliary tract cancer.
Yang J; Farren MR; Ahn D; Bekaii-Saab T; Lesinski GB
Expert Opin Ther Targets; 2017 May; 21(5):485-498. PubMed ID: 28282502
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]